Search results for "mortality"

showing 10 items of 1406 documents

Novelties in COPD prognosis: Evolution of survival indexes

2015

Despite several techniques, such as non-invasive ventilation (NIV), have improved the outcome of the acute exacerbation, COPD remains affected by poor prognosis in the medium and long term. Moreover, the task of predicting prognosis remains a major challenge for respiratory physicians. In order to overcome this limitation, several indexes have been proposed to assess the COPD patient in his/her complexity. The rationale is that, by using numerical indexes physicians may improve their clinical judgment to tailor and share therapeutical choices, i.e. referring the patient for surgery or lung transplantation. On this ground, Almagro et al. recently proposed the CODEX index, as the latest evolu…

Noninvasive VentilationSurvivalPrognosiPrognostic indexesSettore MED/10 - Malattie Dell'Apparato RespiratorioPrognosismortalitySurvival RatePulmonary Disease Chronic ObstructivePrognostic indexeLung transplantationCOPD; Extracorporeal carbon dioxide removal; Lung surgery; Lung transplantation; Non-invasive ventilation (NIV); Prognosis; Prognostic indexes; SurvivalExtracorporeal carbon dioxide removalHumansCOPDNon-invasive ventilation (NIV)Lung surgery
researchProduct

Vitamin D 25OH Deficiency and Mortality in Moderate to Severe COVID-19: A Multi-Center Prospective Observational Study.

2022

IntroductionSeveral studies and meta-analyses suggested the role of vitamin D 25OH in preventing severe forms of coronavirus disease 2019 (COVID-19). However, the evidence on the clinical benefits of vitamin D 25OH adequacy in patients hospitalized for COVID-19 remain conflicting and speculative. We aimed to investigate the association between vitamin D 25OH serum levels and mortality in hospitalized patients with moderate to severe COVID-19.MethodThis prospective observational multicentre study included 361 consecutive patients with moderate to severe COVID-19 admitted to the Italian hospitals involved in the NUTRI-COVID19 trial from March to August 2020. For each patient, serum vitamin D …

Nutrition and DieteticsEndocrinology Diabetes and MetabolismCOVID-19 hospitalized patients mortality propensity score (PS) vitamin D 25OHFood ScienceFrontiers in nutrition
researchProduct

RESUMEN EJECUTIVO DEL CONSENSO DE EXPERTOS SOBRE LA EFICACIA Y SEGURIDAD DE LOS iDPP-4 EN EL TRATAMIENTO DE PACIENTES CON DIABETES Y COVID-19

2021

Resumen Antecedentes El objetivo de este consenso es esclarecer el papel de los iDPP-4 en el manejo de los pacientes con diabetes durante la pandemia por COVID-19. Material y metodos Se llevo a cabo una busqueda bibliografica en PubMed (diciembre 2019-febrero de 2021). Se empleo la metodologia Oxford y se establecieron de forma consensuada posibles recomendaciones. Resultados La diabetes parece ser un factor independiente en la enfermedad de COVID-19 (evidencia 2b). No se demuestra mayor riesgo de contagio con iDPP-4 (evidencia 2b), y su uso ha demostrado ser seguro (evidencia 2b). Los iDPP-4 pueden presentar un cierto beneficio en la reduccion de la mortalidad, particularmente su uso intra…

Nutrition and DieteticsdiabetesEndocrinology Diabetes and MetabolismAntidiabetic drugsDiabetesCOVID-19antidiabetic drugsiDPP-4mortalityArticleEndocrinologymortalidadMortalityfármacos antidiabéticosEndocrinologia, Diabetes Y Nutricion
researchProduct

Ocean acidification impairs vermetid reef recruitment

2014

Vermetids form reefs in sub-tropical and warm-temperate waters that protect coasts from erosion, regulate sediment transport and accumulation, serve as carbon sinks and provide habitat for other species. The gastropods that form these reefs brood encapsulated larvae; they are threatened by rapid environmental changes since their ability to disperse is very limited. We used transplant experiments along a natural CO2 gradient to assess ocean acidification effects on the reef-building gastropod Dendropoma petraeum. We found that although D. petraeum were able to reproduce and brood at elevated levels of CO2, recruitment success was adversely affected. Long-term exposure to acidified conditions…

Ocean Acidification International Coordination Centre (OA-ICC)SalinityTemperateSurvivalAbundance per areainorganicAlkalinityIncubation durationExperimentTemperature waterCarbon inorganic dissolvedNeogoniolithon brassica-floridaCalculated using seacarb after Nisumaa et al 2010Aragonite saturation stateAlkalinity totalSalinity standard errortotalCO2 ventMortality SurvivalpHReproductionTemperaturePartial pressure of carbon dioxide (water) at sea surface temperature (wet air) standard errorStrontium/Calcium ratiodissolvedMagnesium/Calcium ratioCarbonate ionPartial pressure of carbon dioxide (water) at sea surface temperature (wet air)Field experimentstandard errorEarth System ResearchRecruitmentMortality/SurvivalFOS: Medical biotechnologygeographic locationsPotentiometric titrationCalcite saturation stateCoveragePotentiometricwaterSiteGrowth MorphologyFigureAlkalinity total standard errorBenthosReplicateMediterranean SeaOcean Acidification International Coordination Centre OA ICCAnimaliaBicarbonate ionNeogoniolithon brassica floridaLONGITUDETemperature water standard errorCalculated using seacarb after Nisumaa et al. (2010)SpeciespH standard errorCalculated using CO2SYSfungiCarbonate system computation flagFugacity of carbon dioxide (water) at sea surface temperature (wet air)CarbonAragonite saturation state standard errorPartial pressure of carbon dioxide water at sea surface temperature wet airCarbon dioxideMolluscaGrowth/MorphologySingle speciesLATITUDEBenthic animalsFugacity of carbon dioxide water at sea surface temperature wet airMagnesium Calcium ratioCoast and continental shelfDendropoma petraeumStrontium Calcium ratio
researchProduct

Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France.

2012

Long-term population-based survival data detailed by cancer subtype are important to measure the overall outcomes of malignancy managements. We provide net survival estimates at 1, 3, 5 and 10-year postdiagnosis on 37,549 hematological malignancy (HM) patients whose ages were >15 years, diagnosed between 1989 and 2004 and actively followed until 2008 by French population-based cancer registries. These are, to our knowledge, the first unbiased estimates of 10-year net survival in HMs detailed by subtypes. HMs were classified according to the International Classification of Diseases-Oncology 3. Net survival was estimated with the unbiased Pohar-Perme method. The results are reported by sex an…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationFollicular lymphomaMalignancyAge DistributionBiasInternal medicinemedicineHumansRegistriesSex DistributioneducationAgededucation.field_of_studyLeukemiaModels Statisticalbusiness.industryMortality rateLymphoma Non-HodgkinCancerMiddle Agedmedicine.diseasePrognosisHodgkin DiseaseLymphomaCancer registryOncologyHematologic NeoplasmsMyelodysplastic SyndromesImmunologyFemaleFrancebusinessChronic myelogenous leukemiaInternational journal of cancer
researchProduct

Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?

2016

Objectives To better understand the influence of prostate-specific antigen (PSA) screening and other health system determinants on prognosis of prostate cancer, up-to-date relative survival (RS), stage distributions, and trends in survival and incidence in Germany were evaluated and compared with the United States of America (USA). Patients and methods Incidence and mortality rates for Germany and the USA for the period 1999-2010 were obtained from the Centre for Cancer Registry Data at the Robert Koch Institute and the USA Surveillance Epidemiology and End Results (SEER) database. For analyses on stage and survival, data from 12 population-based cancer registries in Germany and from the SE…

OncologyAdultMalemedicine.medical_specialtyAdolescentUrologyPopulation03 medical and health sciencesProstate cancerYoung Adult0302 clinical medicineAge DistributionPredictive Value of TestsResidence CharacteristicsInternal medicineGermanymedicineSurveillance Epidemiology and End ResultsHumansMass Screening030212 general & internal medicineeducationMass screeningAgedNeoplasm Stagingeducation.field_of_studyRelative survivalbusiness.industryMortality rateIncidence (epidemiology)IncidenceProstatic NeoplasmsReproducibility of ResultsMiddle AgedProstate-Specific Antigenmedicine.diseasePrognosisUnited StatesCancer registry030220 oncology & carcinogenesisbusinessDemographySEER ProgramBJU international
researchProduct

Cancer cure for 32 cancer types: results from the EUROCARE-5 study

2020

Abstract Background Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. Methods 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15–74 years in 1990–2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95…

OncologyAdultMalemedicine.medical_specialtySkin NeoplasmsAdolescentEpidemiologyPopulation03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerLife ExpectancyProstateInternal medicineNeoplasmsmedicineHumans030212 general & internal medicineRegistrieseducationThyroid cancerMelanomaComputingMilieux_MISCELLANEOUSAgededucation.field_of_study[SHS.SOCIO]Humanities and Social Sciences/SociologyRelative survivalbusiness.industryMelanomaMortality rateCancerGeneral MedicineMiddle Agedmedicine.disease3. Good healthEuropeSurvival Ratemedicine.anatomical_structure030220 oncology & carcinogenesisQuality of LifeFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct

Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series.

2012

e11056 Background: Breast cancer (BC) is frequent in the elderly and is burdened by high recurrence and death rates, due mostly to undertreatment. Trastuzumab (T), in combination with chemotherapy (CT) or hormonotherapy (HT), is a well-established treatment strategy for early and advanced HER2-positive (HER2+) breast cancer, but has been poorly studied in the elderly setting due to its infrequency. The aim of our study is to assess the safety of T in elderly patients with HER2+ BC. Methods: Between 2005 and 2010, consecutive HER2+ breast cancer patients of ≥70 years of age referred to two oncology centers and that received T-based therapy were retrospectively reviewed. All patients were tr…

OncologyCancer ResearchSeries (stratigraphy)medicine.medical_specialtyChemotherapyEjection fractionbusiness.industryMortality ratemedicine.medical_treatmentGeriatric assessmentmedicine.diseaseBreast cancerOncologyTrastuzumabInternal medicineHER2 Positive Breast CancerMedicinebusinessmedicine.drugJournal of Clinical Oncology
researchProduct

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing live…

2010

Abstract Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibito…

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinIntracellular Signaling Peptides and Proteins - antagonists & inhibitors metabolismKaplan-Meier Estimate312 Clinical medicineProtein-Serine-Threonine KinaseLiver transplantationTHERAPYStudy ProtocolImmunosuppressive Agentendothelial growth-factor renal-cell carcinoma tumor progression rapamycin cancer cyclosporine efficacy therapy target model0302 clinical medicineRENAL-CELL CARCINOMARisk FactorsRecurrenceSurgical oncologyMedicine and Health SciencesLiver Neoplasms - drug therapy enzymology mortality surgerySirolimuProspective StudiesTUMOR PROGRESSIONTransplantation Homologoueducation.field_of_studyliver transplantationTOR Serine-Threonine KinasesLiver NeoplasmsIntracellular Signaling Peptides and ProteinsImmunosuppressionhepatocellular carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCANCER3. Good healthEuropeMulticenter StudyTreatment OutcomeTARGETsirolimusOncologyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaRandomized Controlled TrialmTORCarcinoma Hepatocellular - drug therapy enzymology mortality surgery030211 gastroenterology & hepatologyImmunosuppressive AgentsRCTHumanmedicine.drugCanadamedicine.medical_specialtyCarcinoma HepatocellularTime FactoreducationPopulationLiver Transplantation - adverse effects mortalityProtein Serine-Threonine Kinaseslcsh:RC254-282Disease-Free Survival03 medical and health sciencesInternal medicineGeneticsmedicineTransplantation HomologousHumansComparative StudyRapamycinddc:610educationProtein-Serine-Threonine Kinases - antagonists & inhibitors metabolismKaplan-Meiers Estimatebusiness.industryRisk FactorAustraliaImmunosuppressive Agents - therapeutic useSirolimus - therapeutic useEFFICACYHumans; Liver Transplantation; Hepatocellular Carcinoma; Randomized Controlled Trial; RCT; Multicenter Study; Comparative Study; Rapamycin; mTOR; Sirolimusmedicine.diseaseSurgeryMODELTransplantationClinical trialProspective StudieIntracellular Signaling Peptides and ProteinSirolimusENDOTHELIAL GROWTH-FACTORCYCLOSPORINERAPAMYCINbusiness
researchProduct

Lung tumorspheres as a platform for testing new therapeutic strategies in lung cancer.

2016

e23177Background: Resistance to treatment is one of the causes influencing the high mortality of lung cancer. This feature seems to be dependent of a small subset of special characteristics of self...

OncologyCancer Researchmedicine.medical_specialtyLungbusiness.industryHigh mortalitymedicine.diseasemedicine.anatomical_structureOncologyFeature (computer vision)Internal medicinemedicineTreatment resistancebusinessLung cancer
researchProduct